tradingkey.logo

Evolus Inc

EOLS

6.420USD

-0.100-1.53%
終値 09/18, 16:00ET15分遅れの株価
414.98M時価総額
損失額直近12ヶ月PER

Evolus Inc

6.420

-0.100-1.53%
詳細情報 Evolus Inc 企業名
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
企業情報
企業コードEOLS
会社名Evolus Inc
上場日Feb 08, 2018
最高経営責任者「CEO」Mr. David Moatazedi
従業員数332
証券種類Ordinary Share
決算期末Feb 08
本社所在地520 Newport Center Dr Ste 1200
都市NEWPORT BEACH
証券取引所NASDAQ Global Market Consolidated
United States of America
郵便番号92660-7022
電話番号19492844555
ウェブサイトhttps://www.evolus.com/
企業コードEOLS
上場日Feb 08, 2018
最高経営責任者「CEO」Mr. David Moatazedi
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, Aug 23
更新時刻: Sat, Aug 23
株主統計
種類
株主統計
株主統計
比率
Tang Capital Management, LLC
7.73%
Nantahala Capital Management, LLC
6.49%
Lynch (Timothy Patrick)
6.33%
BlackRock Institutional Trust Company, N.A.
5.64%
Caligan Partners, LP
5.17%
他の
68.65%
株主統計
株主統計
比率
Tang Capital Management, LLC
7.73%
Nantahala Capital Management, LLC
6.49%
Lynch (Timothy Patrick)
6.33%
BlackRock Institutional Trust Company, N.A.
5.64%
Caligan Partners, LP
5.17%
他の
68.65%
種類
株主統計
比率
Hedge Fund
38.42%
Investment Advisor
26.05%
Investment Advisor/Hedge Fund
15.57%
Individual Investor
8.31%
Private Equity
7.59%
Corporation
3.30%
Research Firm
2.02%
Bank and Trust
0.56%
Pension Fund
0.56%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
362
58.85M
90.98%
-2.31M
2025Q1
367
61.71M
95.75%
-6.80M
2024Q4
349
59.00M
93.18%
-8.33M
2024Q3
345
58.57M
92.95%
-9.62M
2024Q2
337
59.72M
95.46%
-6.66M
2024Q1
324
57.99M
95.42%
-6.59M
2023Q4
309
53.87M
93.36%
-7.99M
2023Q3
309
51.63M
90.65%
-8.83M
2023Q2
309
53.08M
93.27%
-5.08M
2023Q1
308
49.88M
88.43%
-4.38M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Tang Capital Management, LLC
5.00M
7.75%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
3.65M
5.66%
+521.19K
+16.65%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.82M
5.93%
-13.22K
-0.34%
Mar 31, 2025
Caligan Partners, LP
2.73M
4.24%
+38.77K
+1.44%
Mar 31, 2025
The Vanguard Group, Inc.
3.22M
5%
+62.66K
+1.98%
Mar 31, 2025
Perceptive Advisors LLC
4.13M
6.4%
-1.02M
-19.76%
Mar 31, 2025
Medy Tox Inc
2.14M
3.31%
-1.24M
-36.82%
Dec 31, 2024
Soleus Capital Management, L.P.
1.08M
1.67%
+382.00K
+54.79%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Sep 6
更新時刻: Sat, Sep 6
銘柄名
比率
SPDR S&P Pharmaceuticals ETF
0.86%
iShares U.S. Pharmaceuticals ETF
0.19%
iShares Micro-Cap ETF
0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.09%
iShares Russell 2000 Growth ETF
0.03%
iShares Russell 2000 ETF
0.02%
Global X Russell 2000 ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Fidelity MSCI Health Care Index ETF
0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
詳細を見る
SPDR S&P Pharmaceuticals ETF
比率0.86%
iShares U.S. Pharmaceuticals ETF
比率0.19%
iShares Micro-Cap ETF
比率0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0.09%
iShares Russell 2000 Growth ETF
比率0.03%
iShares Russell 2000 ETF
比率0.02%
Global X Russell 2000 ETF
比率0.02%
Schwab U.S. Small-Cap ETF
比率0.01%
Fidelity MSCI Health Care Index ETF
比率0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
比率0%
配当金
過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
KeyAI